Your cash under control, without spending your days on it.
Redmontis gives biotech executives a clear view of runway and cash at any moment. You decide fast, you answer the board without reopening a spreadsheet, and you keep your time for what creates value: the science, execution and fundraising.
Built for biotech CEOs and CFOs.
Interface preview, demonstration data. See the 7 screens →
Redmontis lets me move quickly from an operational assumption to a strategic decision. I can simulate the impact of a trial delay on our runway and walk into the board with clear, defensible scenarios.
Grégoire Serra · Chairman & CEO of DolinnovClinical-stage biotech · France
As a CFO, I spent many hours rebuilding Excel models before every board. Christophe's tool gave us a reliable runway and presentation-ready scenarios, without starting from a blank page.
Jonathan Susini · former CFO, Scarcell TherapeuticsCell therapy, Phase I/II · France
Too many hours lost on spreadsheets, at the wrong moment.
You should be advancing the science and securing funding. Instead, every board, every investor question reopens an Excel file that you're the only one to understand.
4 to 6 weeks per board
Rebuilding the model and preparing the reporting before every quarterly board, on your time as an executive.
Limited responsiveness
"How much runway do we have left?" The answer requires a calculation, not a glance.
Three definitions of runway
The CEO, the CFO and the investor often don't have the same number around the table.
Sources: EY Biotech Beyond Borders 2026 (June 2026, publicly traded biotechs US & EU); PitchBook Q4 2025 Biopharma VC Report (February 2026).
Time reclaimed, decisions made with more confidence.
The 3-hour turnaround and the 4-to-6-week manual rebuild: feedback from CEO and CFO users.
- Cash-to-zero date updates on its own
- Alert before the next critical funding milestone
- A single source, shared with your CFO
Know where you stand, without opening a file.
Runway, burn and cash are right there, up to date. You adjust an assumption, the impact recalculates. You steer your cash instead of being driven by it, and you stay focused on the science and the raise.
See the features- A quantified answer in the meeting, not after
- Investor reporting exported in one click
- Same numbers for you, the board and the CFO
Walk into meetings with ready, defensible numbers.
When an investor asks about the impact of a trial delay or a hire, you show the scenario on screen. A clear format, consistent from one meeting to the next, that builds trust without costing you a night of prep.
Request a demoWe are looking for 3 US biotechs to build with.
Redmontis is live and used by biotech CEOs in France. We are now selecting 3 US companies to co-develop the US version: you see the French demo, validate the concept on your numbers, and commit before we build. In exchange: preferential pricing locked for life, direct input on the US product roadmap, and priority onboarding when we launch.
No commitment until you have seen the demo and decided. No product delivered until the 3 commitments are signed.
Apply as a founding customerDo you support biotechs? Redmontis saves you time too.
Funds, biotech hubs, incubators, CPAs: when your companies speak the same financial language, calculate and visualize runway the same way, and present the same Use of Proceeds, everyone moves faster.
Funds & investors
Compare the runway of all your portfolio companies on the same definition and the same assumptions, and spot a cash risk months before it blows up. A holding lost to a poorly anticipated runway costs several million, while the Redmontis tool costs $30,000 per year.
Biotech hubs & networks
Your member companies put together NIH, BARDA and SBIR grant applications with a coherent, traceable cash plan that stands up to reviewer scrutiny. You raise the financial standard across the entire ecosystem.
Incubators & accelerators
A new CEO with a scientific background gets a grip on their financial data faster: accelerated onboarding, good discipline from the start. And an investor-ready file in days, not weeks, which improves the fundraising success rate of your spin-offs.
CPAs & financial advisors
Your clients arrive with structured data and their R&D tax credit documentation (Section 41 IRC) already framed and sourced. The US version of Redmontis will be adapted to support the R&D credit process as it applies in the United States. Fewer hours fixing files, and you establish a higher standard for the whole practice.
The shared benefit: the same language and the same data from one company to the next, time saved for your teams, who focus on execution rather than rebuilding spreadsheets.
From $30,000 per year.
Pricing based on capital under management. All of Redmontis, with no options or surprises. The time reclaimed and the peace of mind in meetings are well worth the spend — judge for yourself on a demo.
See pricing Request a demo